Immodulon, Pioneers in Immuno-oncology

“Our Mission is to improve the lives of patients suffering from life-threatening cancers through novel therapies that boost their immune response and improve the performance of their cancer treatment, enabling them to live happier, healthier and longer lives.”

Pipeline

Immodulon is dedicated to developing novel, safe and effective immunotherapy treatments for cancer patients. We believe that our lead candidate, the immunomodulator IMM-101, will become the backbone therapy across multiple tumour types in combination with any of the four major pillars of cancer therapy: immunotherapy, chemotherapy, radio/ablation therapy and surgery.

IMM-101 is being investigated in a broad clinical programme, these are either Immodulon Sponsored, or Investigator Sponsored Studies.

  • ADVANCED MELANOMA (PHASE II)
  • METASTATIC PANCREATIC CANCER – GLOBAL (PHASE III)
  • METASTATIC PANCREATIC CANCER – INTERNATIONAL (PHASE II)
  • LOCALLY ADVANCED PANCREATIC CANCER (PHASE II)
  • OLIGO-METASTATIC PANCREATIC CANCER (PHASE II)

Latest from Immodulon